Looks like a shorter con job on us to me , the writer is mistaken ????,,MSB may have access to an additional $US67 .5 million ,, they have no debt yet ???
• 92% increase in revenues to US$32.2 million for FY2020, compared with US$16.7 million for FY2019. o 127% increase in milestone revenue from strategic partnerships, to US$25.0 million for FY2020. o 32% increase in royalty revenue on TEMCELL® HS. Inj.1 sales in Japan by licensee JCR Pharmaceuticals (JCR), to US$6.6 million for FY2020.
• 13% reduction in loss after tax (US$77.9 million for FY2020 compared with US$89.8 million for FY2019), even after US$13.8 million increased investment in commercial readiness for the potential US launch of RYONCIL (US$8.8 million for commercial manufacturing activities and US$5.0 million for sales/marketing).
• US$129.3 million (A$188.4 million)2 cash on hand at June 30, 2020, after US$90 million (A$138 million)3 capital raise from global institutional investors in May 2020.
• May have access to up to an additional US$67.5 million over the next 12 months through existing financing facilities and strategic partnerships
- Forums
- ASX - By Stock
- MSB
- Mesoblast, COVID-19 And Trump?
Mesoblast, COVID-19 And Trump?, page-18
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.08 |
Change
-0.045(4.00%) |
Mkt cap ! $1.255B |
Open | High | Low | Value | Volume |
$1.14 | $1.16 | $1.08 | $5.573M | 5.029M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
23 | 387462 | $1.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.09 | 28475 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 252938 | 1.095 |
36 | 303204 | 1.090 |
12 | 117025 | 1.085 |
20 | 949343 | 1.080 |
9 | 90885 | 1.075 |
Price($) | Vol. | No. |
---|---|---|
1.100 | 77410 | 15 |
1.105 | 166708 | 22 |
1.110 | 161080 | 15 |
1.115 | 119478 | 10 |
1.120 | 135440 | 8 |
Last trade - 14.25pm 29/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |